chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Pharyngeal swelling, Swollen tongue
Clinical narrative: Throat was closing; Tongue swelled up; Heavy sweating; Fogging brain; Feeling of passing out; Lips swelled up; Weak; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8733) via an unspecified route of administration in the left arm on 01Apr2021 at 13:45 (at the age of 18-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no allergies to medications, food, or other products. The patient did not receive any concomitant medication within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 19:30, the patient felt that the throat was closing, lips and tongue swelled up, heavy sweating, fogging brain, feeling of passing out and weak. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measure taken as a result of the events experienced included benadryl (MANUFACTURER UNKNOWN). The clinical outcome of the events throat was closing, lips and tongue swelled up, heavy sweating, fogging brain, feeling of passing out and weak were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Adverse event, Body temperature, Diarrhoea, Fatigue
Clinical narrative: Sudden low grade fever (100.2-100.4); Bodyache; GI distress; Frequent loose BM; Nausea; Fatigue; HA; This is a spontaneous report from a contactable nurse, the patient. A 66-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the left arm on 22Feb2021 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included osteoporosis. Concomitant medications included alendronate (MANUFACTURER UNKNOWN) for unknown indication and from unknown date. The patient previously took epinephrine for unknown indication and on an unknown date and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via an unspecified route of administration in the left arm on 01Feb2021 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had been tested for COVID-19.  On 28Mar2021 at 12:00, 36 days after receiving the second dose, the patient experienced sudden low-grade fever (100.2-100.4), body ache, HA(adverse event Nos), GI(Gastro intestinal) distress with nausea, frequent loose BM(bowel movements) and fatigue that lasted for 48 hrs. Symptoms resolved by 3rd day. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. On 30Mar2021, the patient underwent rapid molecular PCR COVID test (Nasal swab) and the result was negative. The clinical outcome of the events slight fever, general body pain, adverse event Nos, distress gastrointestinal, nausea, loose bowel movements and fatigue was resolved on an unknown date.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: Sudden low grade fever (100.2-100.4); Bodyache; GI distress; Frequent loose BM; Nausea; Fatigue; HA; This is a spontaneous report from a contactable nurse, the patient. A 66-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the left arm on 22Feb2021 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included osteoporosis. Concomitant medications included alendronate (MANUFACTURER UNKNOWN) for unknown indication and from unknown date. The patient previously took epinephrine for unknown indication and on an unknown date and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261) via an unspecified route of administration in the left arm on 01Feb2021 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had been tested for COVID-19.  On 28Mar2021 at 12:00, 36 days after receiving the second dose, the patient experienced sudden low-grade fever (100.2-100.4), body ache, HA(adverse event Nos), GI(Gastro intestinal) distress with nausea, frequent loose BM(bowel movements) and fatigue that lasted for 48 hrs. Symptoms resolved by 3rd day. The events resulted in doctor or other healthcare professional office/clinic visit. The patient did not receive any treatment for the reported events. On 30Mar2021, the patient underwent rapid molecular PCR COVID test (Nasal swab) and the result was negative. The clinical outcome of the events slight fever, general body pain, adverse event Nos, distress gastrointestinal, nausea, loose bowel movements and fatigue was resolved on an unknown date.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Pharyngeal swelling, Swelling face
Clinical narrative: This is a spontaneous report from a contactable other healthcare professional. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via intramuscular route of administration in the right arm on 01Apr2021 at 15:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure, knee issues, back problems and bladder issues. The patient was allergic to food, medications, or other products. The patient received unspecified medication within two weeks prior to the vaccination. The patient did not receive any other vaccine within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via intramuscular route of administration in the right arm on 11Mar2021 at 15:00 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021 at 15:30, half an hour after vaccination, the patient felt right side of face and throat were swollen up. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the events right side of face and throat were swollen up were resolved on an unknown date in Apr2021. No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Discomfort, Lymphadenopathy, Varicose vein
Clinical narrative: Some lumps have shown up in veins noticeable in hand veins; Swelling of lymph nodes near throat.; Bothering of lymph nodes near throat; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 18Mar2021 at 16:15 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient was not allergic to medications, food or other products. The patient did not receive any medications within two weeks prior to the vaccination. The patient did not received any other vaccines within 4 weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021, the patient had some lumps which had shown up in veins noticeable in hand veins and swelling of lymph nodes near throat which was bothering. The patient did not receive any treatment for the events. The clinical outcome of the events some lumps which had shown up in veins noticeable in hand veins and swelling of lymph nodes near throat which was bothering were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster, Herpes zoster oticus, Ophthalmic herpes zoster
Clinical narrative: The vaccination triggered shingles on my head and right eye. The right ear has also got affected; The vaccination triggered shingles on my head and right eye. The right ear has also got affected; The vaccination triggered shingles on my head and right eye. The right ear has also got affected; This is a spontaneous report from a contactable consumer (patient). A 66-year-old male patient received his first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number: EN6205), via an unspecified route of administration on 05Mar2021 13:30 (at the age of 66-years-old) at dose 1, single in the left arm for COVID-19 immunisation. Medical history included BP (blood pressure) abnormal, and gout. The patient has no known allergies, no COVID prior vaccination, and was not tested for COVID post-vaccination. The patient was vaccinated in a hospital. Concomitant medications included metoprolol and allopurinol. On 10Mar2021, the vaccination triggered shingles on the patient's head and right eye. The right ear also got affected. The patient was rushed to the emergency room. Later on, the patient had to visit ophthalmologist and ear specialists who prescribed medications. The events resulted in emergency room visit and doctor or other healthcare professional office/clinic visit. The patient received treatment (unspecified) for the events. Outcome of all the events was recovering.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Vaccination site pain
Clinical narrative: Sore throat; Pain in injection site; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 02Apr2021 at 11:45 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. The medical history of the patient was reported as none. The patient did not have allergies to medications, food, or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 15:45, the patient experienced sore throat and pain in injection site (vaccination site pain). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was reported as unknown if the patient had received any treatment for the reported adverse events. The clinical outcome of the event sore throat and pain in injection site (vaccination site pain) was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, Pyrexia
Clinical narrative: Fever; chills; headache; body aches; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 01Apr2021(at the age of 72-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, asthma and hypertension. The patient did not have allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202), via an unspecified route of administration in the left arm on 11Mar2021 at 12:45 as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 01:00  the patient experienced fever, chills, headache and  body aches. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event fever, chills, headache and body aches were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Dyspnoea, Headache, Lung disorder, Nausea
Clinical narrative: Bad intermittent headache resembling a migraine; Felt a pain in chest each time patient breathed in; Felt a consistent heaviness orpressure in my lungs; Occasional shortness of breath.; Minor nausea; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Mar2021 at 10:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient did not had any relevant medical history. The patient was not allergic to food, medications, or other products. The patient did not receive any medications within two weeks prior to the COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 10:30, the patient felt a consistent heaviness or pressure in lungs, occasional shortness of breath and minor nausea which was present at times. On the same day at 10:45, within 15 minutes of receiving the vaccine, the patient felt a pain in chest each time the patient breathed in which lasted for an hour. On 01Apr2021 and 02Apr2021, the patient had bad intermittent headache resembling a migraine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event felt a pain in chest each time the patient breathed in was resolved on 26Mar2021 in about one hour. The clinical outcome of the events occasional shortness of breath, minor nausea, bad intermittent headache resembling a migraine, and consistent heaviness or pressure in lungs were not resolved at the time of this report  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Feeling abnormal, Hypertension, Speech disorder, Swelling
Clinical narrative: the right side of my neck swelled up; I could not speak or think properly; I could not speak or think properly; blood pressure was 177 over 80 and kept going up/got to 205 over 100 and they took me to the hospital and it took 3 hours for it to get to a reasonable number of 149 over 80/blood pressure this high; feeling bad; This is a spontaneous report from a contactable consumer (patient). A 52-year-old non-pregnant female patient received the dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: er2613), via an unspecified route of administration on 23Mar2021 12:15 (at the age of 52-years-old) at dose number unknown, single in the left arm for COVID-19 immunisation. Medical history included corn allergy and asthma. The patient was allergic to lots of products in the store. The patient has a safe list from her dermatologist so she knows what kind of shampoo, clothes detergent, etc. she can buy. The patient had no COVID prior vaccination, was not tested for COVID post-vaccination, and was not pregnant at the time of vaccination. Concomitant medications included losartan and citalopram. The patient previously took lisinopril, lactose, and ammonia, and experienced allergies. The patient was vaccinated in a public health department. On 23Mar2021 12:15, the patient started feeling bad immediately. The patient stated, " they asked me to back up and I went left and ran over an orange cone that got stuck under my Prius because I misunderstood them". On 23Mar2021 12:15, the patient's blood pressure was 177/80 and kept going up. The patient's blood pressure got up to 205/100. The patient was brought to the hospital on 23Mar2021 and it took 3 hours for it to get to a reasonable number of 149/80 so the patient could go home. The patient never had her blood pressure this high. The patient was not anxious about getting the shot at all and felt normal before hand and these all happened very quickly. The patient will not get the second dose because she doesn't want to have a stroke. The next morning, on 24Mar2021, the patient's right side of her neck swelled up and she could not speak or think properly. It was reported that the events resulted in emergency room/department or urgent care visit. It was unknown if patient was given treatment for the events. Outcome of the events blood pressure high was recovered on 23Mar2021, and for other events was recovered on an unspecified date in 2021.  Follow-Up (22Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Thinking abnormal
Clinical narrative: the right side of my neck swelled up; I could not speak or think properly; I could not speak or think properly; blood pressure was 177 over 80 and kept going up/got to 205 over 100 and they took me to the hospital and it took 3 hours for it to get to a reasonable number of 149 over 80/blood pressure this high; feeling bad; This is a spontaneous report from a contactable consumer (patient). A 52-year-old non-pregnant female patient received the dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: er2613), via an unspecified route of administration on 23Mar2021 12:15 (at the age of 52-years-old) at dose number unknown, single in the left arm for COVID-19 immunisation. Medical history included corn allergy and asthma. The patient was allergic to lots of products in the store. The patient has a safe list from her dermatologist so she knows what kind of shampoo, clothes detergent, etc. she can buy. The patient had no COVID prior vaccination, was not tested for COVID post-vaccination, and was not pregnant at the time of vaccination. Concomitant medications included losartan and citalopram. The patient previously took lisinopril, lactose, and ammonia, and experienced allergies. The patient was vaccinated in a public health department. On 23Mar2021 12:15, the patient started feeling bad immediately. The patient stated, " they asked me to back up and I went left and ran over an orange cone that got stuck under my Prius because I misunderstood them". On 23Mar2021 12:15, the patient's blood pressure was 177/80 and kept going up. The patient's blood pressure got up to 205/100. The patient was brought to the hospital on 23Mar2021 and it took 3 hours for it to get to a reasonable number of 149/80 so the patient could go home. The patient never had her blood pressure this high. The patient was not anxious about getting the shot at all and felt normal before hand and these all happened very quickly. The patient will not get the second dose because she doesn't want to have a stroke. The next morning, on 24Mar2021, the patient's right side of her neck swelled up and she could not speak or think properly. It was reported that the events resulted in emergency room/department or urgent care visit. It was unknown if patient was given treatment for the events. Outcome of the events blood pressure high was recovered on 23Mar2021, and for other events was recovered on an unspecified date in 2021.  Follow-Up (22Jul2021): Follow-up attempts are completed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Arthralgia, Dizziness, Ear pain, Nausea
Clinical narrative: Lightheaded; Severe upper abdominal pain; Ear pain; Nausea; Joint pain; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right  arm on 02Apr2021 at 11:00 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. The patient's medical history included post-traumatic stress disorder (PTSD), unknown pain disorder, asthma. The patient's drug and vaccine allergy included allergy to influenza vaccine (MANUFACTURER UNKNOWN), naproxen (MANUFACTURER UNKNOWN), dicloxacillin (MANUFACTURER UNKNOWN), CEPHALEXIN, omeprazole (PRILOSEC), etonogestrel (NEXPLANON), bupropion hydrochloride (WELLBUTRIN XL), metoclopramide (REGLAN) and pregabalin (LYRICA). Concomitant medications included paracetamol (TYLENOL) and  acetylsalicylic acid, caffeine, cinnamedrine (MIDOL) for unknown indication from an unknown date. The patient also received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration (at the age of 29-year-old) as a single dose for COVID-19 immunisation.   Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 17:00, the patient experienced light-headedness, severe upper abdominal pain, ear pain, nausea and joint pain. The events did not result in doctor or other healthcare professional office/clinic visit/ emergency visit. It was unknown if therapeutic measures were taken as a result of adverse events. The clinical outcome of the events lightheaded, upper abdominal pain, ear pain, nausea and joint pain was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Neuralgia
Clinical narrative: Searing nerve pain, mostly in both legs; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Mar2021 (at the age of 27-year-old) as a single dose for COVID-19 immunisation. Medical history included polycystic ovarian syndrome (PCOS), asthma and RBBB (right bundle branch block). The patient had a history of allergy to Phenergan. Concomitant medications included calcium levomefolate; drospirenone; ethinylestradiol betadex clathrate (SAFYRAL) and bupropion hydrochloride (WELLBUTRIN), both for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 25Mar2021 at 03:30, the patient had experienced searing nerve pain, mostly in both legs. Adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event searing nerve pain, mostly in both legs was resolving at the time of report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Fatigue, Headache, Myalgia
Clinical narrative: High fever 101.2 chills; muscle pain; injection site swelling; joint pain; headache; tiredness; This is a spontaneous report from a contactable other healthcare professional, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 6201) via an unspecified route of administration in the left arm on 31Mar2021 at 13:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. The patient was allergic to sulfur. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 6201) via an unspecified route of administration in the left arm on 10Mar2021 at 13:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 18:30, the patient experienced high fever of 101.2 chills, muscle pain, injection site swelling, joint pain, headache and tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. Therapeutic measures were not taken as a result of events. The clinical outcome of the events high fever of 101.2 chills, muscle pain, injection site swelling, joint pain, headache and tiredness were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site swelling
Clinical narrative: High fever 101.2 chills; muscle pain; injection site swelling; joint pain; headache; tiredness; This is a spontaneous report from a contactable other healthcare professional, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 6201) via an unspecified route of administration in the left arm on 31Mar2021 at 13:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. The patient was allergic to sulfur. Concomitant medication included levothyroxine (MANUFACTURER UNKNOWN). The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 6201) via an unspecified route of administration in the left arm on 10Mar2021 at 13:45 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 31Mar2021 at 18:30, the patient experienced high fever of 101.2 chills, muscle pain, injection site swelling, joint pain, headache and tiredness. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. Therapeutic measures were not taken as a result of events. The clinical outcome of the events high fever of 101.2 chills, muscle pain, injection site swelling, joint pain, headache and tiredness were resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Diarrhoea, Headache, Pyrexia
Clinical narrative: Fever up to 102F; headache; diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ER8737) via an unspecified route of administration in the left arm on 30Mar2021 at 11:15 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. Medical history included postural orthostatic tachycardia syndrome(POTS) and mental disorder. Concomitant medications included fluoxetine (MANUFACTURER UNKNOWN), melatonin (MANUFACTURER UNKNOWN), ferrous sulfate (IRON) and prenatal vitamin (MANUFACTURER UNKNOWN), all from unknown dates and for unknown indications. The patient previously received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208)via an unspecified route of administration in the left arm on 09Mar2021 at 14:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient had allergies to fentanyl and miconazole. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 30Mar2021 at 17:00, the patient experienced fever up to 102F, headache and diarrhea. The patient did not receive any treatment for the reported events. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The clinical outcome of the event fever, headache and diarrhea was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Breast swelling, Peripheral swelling
Clinical narrative: Swelling in breaststroke and under left arm; Swelling in breaststroke and under left arm; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN8727) via an unspecified route of administration in the left arm on 27Mar2021 at 12:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient was receiving unspecified concomitant medications. The patient previously received penicillin (MANUFACTURER UNKNOWN) and erythromycin (MANUFACTURER UNKNOWN) on unknown dates and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 31Mar2021, the patient experienced swelling in breaststroke and under left arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event swelling in breaststroke and under left arm. The clinical outcome of the event swelling in breaststroke and under left arm was resolving at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Balance disorder, Dyspnoea, Feeling abnormal, Headache, Lethargy
Clinical narrative: Headache; injection site pain; loss of balance; mental fog; congestion; breathing difficulty; lethargy; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 02Apr2021 at 08:15 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included COPD and COVID-19. Concomitant medications included atorvastatin calcium (LIPITOR) and fluticasone propionate, salmeterol xinafoate (ADVAIR) both for an unknown indication and from an unknown date. The patient previously received levaquin for an unknown indication and experienced drug allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 16:00, the patient experienced headache, injection site pain, loss of balance, mental fog, congestion, breathing difficulty and lethargy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. No therapeutic measures were taken as a result of events. The clinical outcomes of the events headache, injection site pain, loss of balance, mental fog, congestion, breathing difficulty and lethargy were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Nasal congestion, Vaccination site pain
Clinical narrative: Headache; injection site pain; loss of balance; mental fog; congestion; breathing difficulty; lethargy; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the arm left on 02Apr2021 at 08:15 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included COPD and COVID-19. Concomitant medications included atorvastatin calcium (LIPITOR) and fluticasone propionate, salmeterol xinafoate (ADVAIR) both for an unknown indication and from an unknown date. The patient previously received levaquin for an unknown indication and experienced drug allergy. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 16:00, the patient experienced headache, injection site pain, loss of balance, mental fog, congestion, breathing difficulty and lethargy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department, or urgent care. No therapeutic measures were taken as a result of events. The clinical outcomes of the events headache, injection site pain, loss of balance, mental fog, congestion, breathing difficulty and lethargy were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Inflammation, Lymphadenopathy
Clinical narrative: 1 large inflamed lymph node; Swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the left arm on 13Mar2021 (at the age of 56-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. The patient did not have any allergies to medications, food, or other products. Concomitant medications included daily multivitamins (MANUFACTURER UNKNOWN) for unknown indication and from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021, the patient reported of swollen lymph nodes; left clavicle (large) & armpit (armpit discovered by doctor). Swollen left clavicle node had then gone down. On 26Mar2021, the patient had swollen lymph nodes on right side back of neck. The patient had one large inflamed lymph node and smaller ones into hair line. They became pink/red, warm, protruding, reduced with ibuprofen but did not go away. It had become more enlarged and irritated in the evening and at night. The adverse events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the Swollen lymph nodes and Inflammation, which included treatment with ibuprofen. The clinical outcome of the events swollen lymph nodes and inflammation were not resolved.  No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash under right arm (hives?); This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received an unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 16:45 (at the age of 59-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 01Apr2021, the patient experienced rash under right arm (hives?). The patient did not receive any treatment for the reported adverse event. The clinical outcome of the event rash under right arm (hives?) was not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Pain, SARS-CoV-2 test
Clinical narrative: Body aches; Chills; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the arm left on 01Apr2021 at 02:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history reported. The patient had no known allergies. The patient did not receive any medications within two weeks of vaccination. The patient underwent lab test and procedures, which included COVID-19 virus test on 10Feb2021 and tested negative. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the arm left on 08Mar2021 at 02:15 (at the age of 42-years-old) for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. On 02Apr2021 at 06:30, the patient experienced body aches, chills and headache. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the reported event included Tylenol. The clinical outcome of the events body aches, chills and headache was recovered on an unknown date in April 2021.   No follow-up attempts are possible. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Pruritus, Urticaria
Clinical narrative: I experienced hives within a half hour on my chest and neck. After 9 days the hives returned on my legs and arms with a itchy, burning sensation.; I experienced hives within a half hour on my chest and neck. After 9 days the hives returned on my legs and arms with a itchy, burning sensation.; I experienced hives within a half hour on my chest and neck. After 9 days the hives returned on my legs and arms with a itchy, burning sensation.; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN#6203) via an unspecified route of administration in the left arm on 21Mar2021 at 11:15 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) 50 mcg from an unknown date for unspecified indication. The patient previously received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER8727) via an unspecified route of administration in the right arm on 28Feb2021 at 14:15 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient did not receive any other vaccines within four weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021 at 00:00 the patient experienced hives within a half hour on chest and neck. After 9 days on 04Apr2021, the hives returned on legs, arms with itchy and burning sensation. The patient did not receive any treatment for the adverse events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events hives, itchy and burning sensation was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Swelling of eyelid
Clinical narrative: Right eyelid was swollen shut; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the arm left on 02Apr2021 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, lot number: EN6207) in the left arm on 12Mar2021 at 15:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not received any other vaccines within four weeks prior to the vaccination. On 01Apr2021, the patient underwent Nasal swab test for COVID-19 and the result was found to be negative.  On 02Apr2021 at 23:00, the patient experienced right eyelid was swollen shut. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported adverse event. The clinical outcome of the event right eyelid was swollen shut was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metallic taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6201) via an unspecified route of administration in the left arm on 10Mar2021 at 10:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. The patient medical history included endometriosis from unknown date. The patient had allergy to corn and nickel. Concomitant medications included spironolactone (MANUFACTURER UNKNOWN) from unknow date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 10Mar2021 minutes after vaccine at 10:15, the patient experienced metallic taste in mouth. The events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The patient did not receive any treatment for the reported event. The clinical outcome of the event metallic taste in mouth was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic, SARS-CoV-2 test, Vaccination site erythema, Vaccination site inflammation, Vaccination site pain
Clinical narrative: the area on my arm where I received the injection turned red; the area on my arm where I received the injection turned red, became inflamed; the area on my arm where I received the injection turned red, became inflamed, and began to itch; rash of tiny bumps around the injection site; rash of tiny bumps around the injection site and it has continued to itch now for two days; site of my injection has been very hard; site of my injection has been very hard and sore; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 25Mar2021 at 15:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. Medical history included inappropriate sinus tachycardia, occipital neuralgia and fruit allergy to bananas. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Concomitant medications included daily multivitamin minerals nos; vitamins nos (CENTRUM) from an unknown date. The patient previously took codeine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced allergy. On 01Apr2021, the patient underwent COVID-19 PCR test (test type: Nasal swab) and tested negative. The patient reported that the site of injection had been very hard and sore since the first dose of Pfizer COVID-19 vaccination on 25Mar2021. One week later on 02Apr2021 at 14:00, the area on arm where the patient received the injection turned red, became inflamed, and began to itch. She then developed what seems to be a rash of tiny bumps around the injection site and it has continued to itch now for two days. The patient do not have any other symptoms so far. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events site of injection very hard and sore, injection site area that turned red, became inflamed and began to itch, rash of tiny bumps around the injection site that has continued to itch were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.